Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 178-179

  Aljurf, M ^a   Al Zahrani, H ^a   Van Lint, M T ^b   Passweg, J R ^c  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

aplastic anemia; identical sibling; transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HLA A ANTIGEN; METHOTREXATE; THYMOCYTE ANTIBODY;

ACQUIRED APLASTIC ANEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; CD34 SELECTION; CONTROLLED STUDY; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; MONONUCLEAR CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIBLING; SURVIVAL RATE;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; HLA ANTIGENS; HUMANS; SIBLINGS; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873465632     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.223     Document Type: Review

References (11)

1. Armand P, Antin JH. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant 2007; 13: 505-516
2. Bacigalupo A, Brand R, Oneto R, Bruno B, Socié G, Passweg J et al. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000; 37: 69-80
3. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949
4. Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin (letter). Blood 1997; 89: 3890-3891
5. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E et al. Bone marrow transplantation for severe aplastic anemia: A randomized controlled study of conditioning regimens. Blood 2007; 109: 4582-4585
6. Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socié G et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: A comparison with conventional conditioning regimen. Haematologica 2009; 94: 1312-1315
7. Al-Zahrani H, Nassar A, Al-Mohareb F, Al-Sharif F, Mohamed S, Al-Anazi K et al. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia. Biol Blood Marrow Transplant 2011; 17: 717-722
8. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118: 2351-2357
9. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400
10. Bacigalupo A, Socié G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: Survival advantage for bone marrow in all age groups. Haematologica 2012; 97: 1142-1148
11. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, Arcese W et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: Results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697